Danaher Co. (NYSE:DHR) EVP Daniel L. Comas sold 7,726 shares of Danaher stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $132.41, for a total value of $1,022,999.66. Following the transaction, the executive vice president now owns 119,095 shares in the company, valued at approximately $15,769,368.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of NYSE DHR opened at $130.32 on Tuesday. The company has a current ratio of 2.18, a quick ratio of 1.74 and a debt-to-equity ratio of 0.32. Danaher Co. has a one year low of $94.59 and a one year high of $134.67. The stock has a market capitalization of $93.86 billion, a price-to-earnings ratio of 28.83, a PEG ratio of 2.53 and a beta of 1.02.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, April 18th. The conglomerate reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.06. Danaher had a return on equity of 11.61% and a net margin of 12.04%. The firm had revenue of $4.88 billion for the quarter, compared to the consensus estimate of $4.80 billion. During the same quarter in the previous year, the company posted $0.99 earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, equities research analysts anticipate that Danaher Co. will post 4.77 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of DHR. Canton Hathaway LLC lifted its position in shares of Danaher by 8.7% in the first quarter. Canton Hathaway LLC now owns 12,886 shares of the conglomerate’s stock worth $1,701,000 after buying an additional 1,036 shares during the last quarter. Abacus Planning Group Inc. lifted its position in shares of Danaher by 52.3% in the fourth quarter. Abacus Planning Group Inc. now owns 9,979 shares of the conglomerate’s stock worth $225,000 after buying an additional 3,428 shares during the last quarter. Municipal Employees Retirement System of Michigan acquired a new stake in shares of Danaher in the fourth quarter worth about $1,705,000. IHT Wealth Management LLC lifted its position in shares of Danaher by 5.1% in the fourth quarter. IHT Wealth Management LLC now owns 2,023 shares of the conglomerate’s stock worth $209,000 after buying an additional 98 shares during the last quarter. Finally, Findlay Park Partners LLP lifted its position in shares of Danaher by 0.9% in the first quarter. Findlay Park Partners LLP now owns 4,635,000 shares of the conglomerate’s stock worth $611,913,000 after buying an additional 40,000 shares during the last quarter. Hedge funds and other institutional investors own 76.98% of the company’s stock.
A number of research analysts have recently weighed in on DHR shares. Janney Montgomery Scott upgraded Danaher from a “neutral” rating to a “buy” rating in a report on Monday, February 25th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $140.00 price target on shares of Danaher in a report on Monday, March 4th. UBS Group lifted their price target on Danaher from $125.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, February 26th. Deutsche Bank lifted their price target on Danaher to $130.00 and gave the company a “buy” rating in a report on Tuesday, February 26th. Finally, Jefferies Financial Group lifted their price target on Danaher to $140.00 and gave the company a “buy” rating in a report on Tuesday, February 26th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $131.75.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: Price-Sales Ratio
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.